Roche steers Gazyva into a new PhIII program after combo shows promise in lupus nephritis study

Roche is working on putting together a late-stage study for its monoclonal antibody Gazyva in patients with severe kidney disease associated with lupus after a combination approach helped patients in a mid-stage study.